Status: Recruiting
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Participants needed: 115
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Medicenna Therapeutics, Inc.Updated: Jul 9, 2025Locations: 27
Eligibility criteria
Aged at least 18 years (inclusive at the time of informed consent). [+8]
Prior systemic anti-cancer therapy including investigational agents within 4 wee... [+16]